[THE INVESTOR]
Celltrion Inc. announced on June 16 that it has applied for a permit to carry out human clinical tests for Remsima SC.
Celltrion is an Incheon-based biotechnology firm headed by
Seo Jung-jin.
Remsima SC is a new line of the autoimmune disease treatment Remsima. Unlike Remsima that requires intravenous injection, Remsima SC can be administered by the patient through subcutaneous injection, the company said. Remsima is a biosimilar based on Remicade developed by Jansen Global Services.
The clinical trials will be conducted on patients suffering from Crohn’s Disease, rheumatoid arthritis and ulcerative colitis.
Celltrion said that applications for clinical trials will also be filed in overseas markets including those in Europe and South America.
The company hopes to receive approval both here and abroad to roll out the product in 2018.
By Choi He-suk (
cheesuk@heraldcorp.com)